Human Growth Hormone hGH Market Report 2025 (Global Edition)

Global Human Growth Hormone hGH Market Report 2025 Market Size Split by Type (Recombinant Human Growth Hormone rhGH, Human Growth Hormone rhGH), by Application (Growth Hormone Deficiency, Turner Syndr...

Human Growth Hormone hGH Market Report Description

We have various report editions of Human Growth Hormone hGH Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Human Growth Hormone hGH Market Insights Video

Key Developments:

• November 2022:

Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis
Texas-based Lumos is developing the drug candidate LUM-201, a small molecule that Merck previously studied in patients with growth hormone deficiency, in the belief it promotes secretion of the hormone from the pituitary gland. However, the oral treatment of Lumos Pharma has failed to match up to Novo Nordisk’s injected drug Norditropin at the interim analysis of a phase 2 trial. But with growth in the Norditropin arm exceeding expectations, Lumos has pinned the blame on baseline imbalances.

• September 2019:

Novo Nordisk’s somapacitan shows favourable profile in GHD trial
The company has reported positive data from the Phase II REAL 3 clinical trial of somapacitan in children with growth hormone deficiency (GHD). The drug has demonstrated safety, efficacy and tolerability comparable to that of once-daily Norditropin (somatropin) after one year. An improved efficacy has been reported for the highest somapacitan dose.

• May 2016:

Genentech has received approval for hGH in USA:
Genentech has received approval to market its recombinant human growth hormone product, Nutropin, for the treatment of short stature caused by GH deficiency in the USA. The approval came on the same day that Eli Lilly's period of orphan drug exclusivity for its Humatrope (somatropin) product ran out.
Nutropin was Genentech's second hGH product in the market - its Protropin version, first launched in 1985, is slightly different in structure.

• January 2022:

FDA snubs new growth deficiency med somatrogon, developed by Pfizer and partner OPKO Health:
The FDA has rejected somatrogon, a potential treatment for pediatric growth hormone deficiency. Pfizer lost a first-mover advantage for a long-acting pediatric growth hormone deficiency drug in the U.S. when Ascendis Pharma won an FDA go-ahead in August for Skytrofa, which is also given once every week.
    
 

Top Companies Market Share in Human Growth Hormone hGH Industry: (In no particular order of Rank)

• Eli Lilly and Company
• Ferring Holding SA
• Genentech
• Merck Co.
• Novo Nordisk
• Pfizer
• Sandoz International GmbH
• Ipsen
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Asia Pacific is anticipated to witness highest CAGR in Human Growth Hormone hGH market during the forecast period:

North America is predicted to make up the greatest portion of the market due to excellent reimbursement conditions, an established healthcare infrastructure, considerable government initiatives, and rising healthcare awareness. The presence of major firms in the area also facilitates greater access to innovative medications, which benefits the North American market. Several major companies with U.S. headquarters, including Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., provide a variety of human GH medicines in the area.However, Asia-Pacific is expected to register the highest CAGR in terms of revenue during the forecast period, owing to the increase in population and rise in awareness amongst the population.

The current report Scope analyzes Human Growth Hormone hGH Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Human Growth Hormone hGH Market Analysis

Type Segment Analysis of Human Growth Hormone hGH Market

This report categorizes competitors in the pharmaceutical and healthcare market based on their product offerings and business models. It includes key details such as definitions, benefits, applications, technological advancements, and regional advantages for each type of pharmaceutical product, including small molecule drugs, biologics, and biosimilars.

Market growth figures, such as market share percentages, revenue, and growth rates (e.g., CAGR), are provided for each segment over the specified period (2019-2023). The report covers various segments

Type of Human Growth Hormone hGH analyzed in this report are as follows:

• Recombinant Human Growth Hormone rhGH
• Human Growth Hormone rhGH

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Human Growth Hormone hGH Industry. Request a Free Sample PDF!

Synthetic human growth hormone was developed in 1985, but FDA approved the usage of drug only for specific disorders. For instance, it is commonly used in children for treating short stature of unknown cause as well as poor growth due to a number of medical causes.Further, awareness regarding turner syndrome is rising and thus hGH use in this syndrome is creating opportunities for the growth of market.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Human Growth Hormone hGH Route of Administration Segment Analysis

Injecting hGH directly into muscles results in quick absorption of hormone in bloodstream. Because there is more blood in muscle tissue. Moreover, holding capacity of muscle tissue is relatively more than skin tissue. Hence hGH is widely given intramuscular route of administration.

• Intravenous
• Intramuscular
• Subcutaneous
• Oral

Human Growth Hormone hGH Distribution Channel Segment Analysis

By Distribution Channel:

Hospital pharmacy dominate the market in terms of distribution of hGH. This can be attributed owing to large population visit hospitals for the treatment of growth disorders.

• Hospital Pharmacy
• Retail Pharmacy
• Clinics
• Online Pharmacy

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion